Raymond James Downgrades Apellis Pharmaceuticals (APLS) to Market Perform

April 1, 2026 3:37 AM

Raymond James analyst Steven Seedhouse downgraded Apellis Pharmaceuticals (NASDAQ: APLS) from Outperform to Market Perform.The analyst comments: "We are downgrading ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found